Here's Why Acadia Pharmaceuticals Inc. Is Soaring Today
In response to Acadia Pharmaceuticals (NASDAQ: ACAD) reporting blow-out earnings and sharing upbeat guidance, shares of the commercial-stage biopharma, which focuses on diseases of the central nervous system, were trading 13.9% higher as of 1:35 p.m. EDT on Wednesday.
Here's a review of the key financial numbers from the second quarter:
Acadia also shared a few non-financial highlights from the quarter with investors:
Source: Fool.com
Acadia Pharmaceuticals Stock
€17.64
2.890%
With 29 Buy predictions and 1 Sell predictions Acadia Pharmaceuticals is one of the favorites of our community.
As a result the target price of 31 € shows a very positive potential of 75.79% compared to the current price of 17.64 € for Acadia Pharmaceuticals.
